NDAORALFOR SOLUTION
Approved
Feb 2024
Lifecycle
LOE Approaching
Competitive Pressure
35/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEGUBETI is an oral solution combining acetylcysteine and lysine, approved in February 2024 by the FDA as an NDA. The mechanism of action and specific therapeutic indications are not publicly detailed in available data. This formulation represents a combination approach to respiratory or mucosal health support.
LOE Approaching3mo to LOE
With LOE approaching in February 2027, the commercial team faces urgent generic erosion planning and may prioritize cost-containment and retention strategies over growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on LEGUBETI at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.